Each year, tens of thousands of infants arrive at hospitals struggling to breathe from viral infections, and medicine has long faced a quiet failure: it cannot tell which children will heal fully and which will carry the burden of asthma or chronic lung disease into childhood. A $52 million consortium led by Michigan Medicine, spanning ten children's hospitals across the United States, now undertakes the patient work of answering that question — following 1,500 young children through their earliest years to map the biological, microbial, and environmental forces that shape a lung's fate. It is
NIH Awards $52M to Study Why Some Infants Develop Lasting Lung Infections
Infants and toddlers hospitalized with viral lower respiratory tract infections face risk of lasting respiratory complications including asthma and chronic lung disease.
We don't know which children will recover completely
Mark
So they're studying 1,500 kids across ten hospitals. That's a real commitment. But what's the actual gap they're trying to fill?
Mimi
Right now, when a child gets hospitalized with bronchiolitis or pneumonia, doctors can treat the acute infection, but they can't tell you whether that child will be fine in six months or dealing with asthma for years. It's basically a coin flip from the clinician's perspective.
Luke
Wait—they can't predict outcomes at all? Or they just can't predict them well?
Mimi
They have very limited ability. Some children recover completely. Others have repeated infections. Some develop chronic respiratory disease. The patterns exist, but doctors don't know which child is which.
Mark
So the study is trying to find the biological markers that would let them predict it?
Mimi
Exactly. They're looking at immune response, the virus itself, the airway microbiome, environmental exposures—all together, not separately. They want to find patterns.
Luke
How long will they follow these kids?
Mimi
At least to ages four or five. So they'll have years of data on how each child's lungs actually develop.
Mark
And the ten hospitals across the country—that's to capture different environments?
Mimi
Yes. Different climates, pollution levels, socioeconomic backgrounds. They want to understand how respiratory illness affects children in different circumstances.
Luke
Do we know if this will actually lead to treatments, or is it purely diagnostic?
Mimi
The hope is that identifying high-risk children early could guide prevention and treatment approaches down the line. But this study is foundational—it's about understanding the patterns first.
Mark
And this is just year one of funding?
Mimi
Right. The NHLBI approved the first year. There's more to come if the work shows promise.
O Pulso
- Doctors currently have almost no reliable way to predict which hospitalized infants will recover fully from viral respiratory infections and which will develop lasting conditions like asthma — a gap that leaves families and clinicians navigating in the dark.
- Viral lower respiratory infections are among the leading causes of infant hospitalization in the U.S., making the stakes of this uncertainty not merely clinical but urgent and widespread.
- The SPIN VINYL study will enroll 1,500 children under two across ten major hospitals, combining lung function testing, imaging, environmental tracking, and advanced molecular analysis in one of the most comprehensive pediatric respiratory investigations ever attempted.
- Researchers are deliberately casting a wide geographic and demographic net — from Philadelphia to Oakland to Texas — to capture how climate, air quality, and socioeconomic conditions shape outcomes alongside biology.
- If the study succeeds in identifying biological signatures of risk, clinicians could one day flag vulnerable children early — including premature infants and those with congenital heart disease — and intervene before chronic disease takes hold.
Each year, tens of thousands of infants arrive at hospitals struggling to breathe from viral infections, and medicine has long faced a quiet failure: it cannot tell which children will heal fully and which will carry the burden of asthma or chronic lung disease into childhood. A $52 million consortium led by Michigan Medicine, spanning ten children's hospitals across the United States, now undertakes the patient work of answering that question — following 1,500 young children through their earliest years to map the biological, microbial, and environmental forces that shape a lung's fate. It is, at its core, an attempt to replace uncertainty with foresight, and helplessness with the possibility of early intervention.
When a toddler arrives at the hospital struggling to breathe from a viral infection, the doctors treating them face a stubborn uncertainty: some of these children will recover completely within weeks. Others will spend years battling recurrent respiratory problems, or develop asthma and chronic lung disease. Right now, clinicians have almost no way to predict which path any individual child will take.
A new $52 million research effort, led by Michigan Medicine and funded by the National Heart, Lung, and Blood Institute, aims to close that gap. The study — called SPIN VINYL — will enroll 1,500 children between birth and two years old who are hospitalized with viral lower respiratory tract infections, following them through at least ages four or five. Ten major children's hospitals across the country are participating, from the Children's Hospital of Philadelphia to UCSF Benioff to Texas Children's, a geographic spread designed to capture how climate, pollution, and socioeconomic circumstance shape outcomes alongside biology.
Researchers will collect far more than standard clinical data. They will measure lung function directly, conduct imaging studies, track environmental exposures like air pollution and secondhand smoke, and perform advanced molecular analyses examining how each child's immune system, the infecting virus, and the bacteria living in their airways all interact. Peter Mourani, the pediatric critical care physician leading the project, puts the problem plainly: the field currently has very limited ability to predict a young child's trajectory after a serious respiratory infection.
The consortium's ambition is to identify measurable biological signatures — markers that could one day allow clinicians to recognize high-risk children early, including those born prematurely or with congenital heart disease, and guide new approaches to prevention and treatment. For now, the study represents a serious institutional commitment to one of pediatric medicine's most persistent open questions: why do some children's lungs recover completely, while others do not?
When a toddler arrives at the hospital struggling to breathe from a viral infection, doctors face a stubborn uncertainty: some of these children will recover completely within weeks, their lungs returning to full function. Others will spend years battling recurrent respiratory problems. A few will develop asthma or chronic lung disease. Right now, clinicians have almost no way to predict which path any individual child will take.
That gap in medical knowledge is what a new $52 million research effort aims to close. Michigan Medicine is leading a consortium of ten major children's hospitals across the United States in a study called SPIN VINYL—Systematic Phenotyping and Endotyping in Viral Infections in the Young Lung. The National Heart, Lung, and Blood Institute has approved the first year of funding for what researchers describe as a systematic attempt to understand why young children respond so differently to the same viral infections.
The study will enroll 1,500 children between birth and two years old who are hospitalized with viral lower respiratory tract infections—conditions like bronchiolitis, pneumonia, and pediatric acute respiratory distress syndrome. Researchers will follow these children through at least ages four or five, collecting far more than the standard clinical notes. They will measure lung function directly, perform imaging studies, track environmental exposures like air pollution and secondhand smoke, monitor sleep and activity patterns, and conduct advanced molecular analyses to examine how each child's immune system, the specific virus involved, and the bacteria living in their airways all interact.
Peter Mourani, a pediatric critical care physician at Michigan Medicine who is leading the project, frames the problem plainly: "Right now, when a young child is hospitalized with a viral respiratory infection, we have very limited ability to predict what their trajectory will be." The question matters because viral lower respiratory infections send tens of thousands of infants and toddlers to hospitals each year in the United States. Early-life respiratory illness has been linked to later respiratory problems—recurrent wheezing, asthma, reduced lung function—but the biological reasons for these different outcomes have remained largely mysterious.
The consortium is deliberately national in scope. Beyond Michigan Medicine, the enrolling sites include the Children's Hospital of Philadelphia, Arkansas Children's Hospital, Children's Hospital Colorado, UCSF Benioff Children's Hospital in both San Francisco and Oakland, Texas Children's Hospital, Johns Hopkins All Children's Hospital, Nationwide Children's Hospital, and Children's National Medical Center. This geographic spread is intentional: researchers want to understand how respiratory illness affects children across different climates, pollution levels, socioeconomic circumstances, and demographic backgrounds. Michigan Medicine serves as the clinical coordinating center.
The research team will examine multiple potential contributors to different outcomes. A child's underlying biology and immune response matter. The characteristics of the infecting virus matter. The composition of bacteria in the child's airways—the airway microbiome—may matter. Environmental factors like air quality and tobacco smoke exposure almost certainly do. Mourani notes that these factors do not operate in isolation: "A child's underlying susceptibility, the virus itself, the way the immune system responds, and the environment in which that child lives may all contribute." By studying them together rather than separately, the consortium hopes to identify patterns that explain why children follow such different paths.
The ultimate goal is to develop measurable biological signatures—markers that clinicians could use to identify which children are at higher risk for poor outcomes, including those born prematurely and those with congenital heart disease. If researchers can recognize these patterns early, they might eventually guide new approaches to prevention and treatment. For now, the study represents a significant institutional commitment to answering a fundamental question in pediatric respiratory health: why do some children's lungs recover completely while others do not?
Citações Notáveis
When a young child is hospitalized with a viral respiratory infection, we have very limited ability to predict what their trajectory will be.— Peter Mourani, M.D., principal investigator, Michigan Medicine
By studying these factors together, rather than in isolation, we hope to identify patterns that explain why children follow very different paths after an early viral infection.— Peter Mourani, M.D.
Quer a matéria completa?
Leia o original em News-Medical ↗
Science & Space